Kim Ju-El, Lee Jong-Won, Cha Gi Doo, Yoon Jeong-Kee
Department of Systems Biotechnology, Chung-Ang University, Anseong-si 17546, Gyeonggi-do, Republic of Korea.
Biomimetics (Basel). 2025 Jan 14;10(1):49. doi: 10.3390/biomimetics10010049.
Diabetes mellitus (DM) is a fatal metabolic disease characterized by persistent hyperglycemia. In recent studies, mesenchymal stem cell (MSC)-derived exosomes, which are being investigated clinically as a cell-free therapy for various diseases, have gained attention due to their biomimetic properties that closely resemble natural cellular communication systems. These MSC-derived exosomes inherit the regenerative and protective effects from MSCs, inducing pancreatic β-cell proliferation and inhibiting apoptosis, as well as ameliorating insulin resistance by suppressing the release of various inflammatory cytokines. Consequently, MSC-derived exosomes have attracted attention as a novel treatment for DM as an alternative to stem cell therapy. In this review, we will introduce the potential of MSC-derived exosomes for the treatment of DM by discussing the studies that have used MSC-derived exosomes to treat DM, which have shown therapeutic effects in both type 1 and type 2 DM.
糖尿病(DM)是一种以持续性高血糖为特征的致命性代谢疾病。在最近的研究中,间充质干细胞(MSC)衍生的外泌体作为一种针对各种疾病的无细胞疗法正在进行临床研究,因其具有与天然细胞通讯系统极为相似的仿生特性而受到关注。这些MSC衍生的外泌体继承了MSC的再生和保护作用,可诱导胰腺β细胞增殖并抑制细胞凋亡,还能通过抑制多种炎性细胞因子的释放来改善胰岛素抵抗。因此,MSC衍生的外泌体作为干细胞疗法的替代方案,作为一种治疗DM的新方法已引起关注。在本综述中,我们将通过讨论使用MSC衍生的外泌体治疗DM的研究来介绍其治疗DM的潜力,这些研究已在1型和2型DM中均显示出治疗效果。